Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Peptide containing doai
Reexamination Certificate
2005-06-07
2008-07-22
Carlson, Karen Cochrane (Department: 1656)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Peptide containing doai
C424S429000, C530S395000, C427S429000
Reexamination Certificate
active
07402562
ABSTRACT:
An orthokeratological procedure is provided that prevents or retards relaxation of corneal tissue back to the original anterior curvature of the cornea. The procedure comprises applying a stabilizing agent that comprises fibril associated collagens with interrupted triple helices (FACITs) and/or small leucine-rich repeat proteoglycans (SLRPs) to the stabilize corneal tissue in a preselected shape.
REFERENCES:
patent: 5270051 (1993-12-01), Harris
patent: 5409731 (1995-04-01), Nakagawa et al.
patent: 5788957 (1998-08-01), Harris
patent: 6132735 (2000-10-01), Harris et al.
patent: 6218360 (2001-04-01), Cintron et al.
patent: 6537545 (2003-03-01), Karageozian et al.
patent: 2001/0016731 (2001-08-01), DeVore et al.
Reddy et al. (1999) Protection against UVB inactivation (in vitro) of rat lens enzymes by natural antioxidants. Mol Cell Biochem. vol. 194, issues 1-2, pp. 41-45.
Scott J. E. (1996) “Proteodermatan and proteokeratan sulfate (decorin, lumican/fibromodulin) proteins are horseshoe shaped. Implications for their interactions with collagen”, Biochemistry, vol. 35, No. 27, pp. 8795-8799.
Scott J. E. (1992) “Supramolecular organization of extracellular matrix glycosaminoglycans, in vitro and in the tissues”, FASEB J., vol. 6, No. 9, pp. 2639-2645.
Iozzo R. V. (1999) “The biology of the small leucine-rich proteoglycans. Functional network of interactive proteins”, J. Biol. Chem., vol. 274, No. 27, pp. 18843-18846.
Dublet et al. (1991) “Type XIV collagen, a new homotrimeric molecule extracted from fetal bovine skin and tendon, with a triple helical disulfide-bonded domain homologous to type IX and type XII collagens”, J. Biol. Chem., vol. 266, No. 11, pp. 6853-6858.
Chakravarti et al. (1998) Lumican regulates collagen fibril assembly: skin fragility and corneal opacity in the absence of lumican, J. Cell Biol., vol. 141, No. 5, pp. 1277-1286.
Quantock et al. (2003) Annulus of collagen fibrils in mouse cornea and structural matrix alterations in a murine-specific keratopathy, Invest. Ophthalmol. Vis. Sci., vol. 44, No. 5, pp. 1906-1911.
DeVore Dale P.
DeWoolfson Bruce H.
Carlson Karen Cochrane
Euclid Systems Corporation
Finnegan Henderson Farabow Garrett & Dunner LLP
Liu Samuel Wei
The Bruce H. DeWoolfson Irrevocable Family Trust
LandOfFree
Composition for stabilizing corneal tissue during or after... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Composition for stabilizing corneal tissue during or after..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Composition for stabilizing corneal tissue during or after... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3963459